CAP Comments on CMS Antifraud Efforts, Urges Reevaluation of MolDX Program
The College of American Pathologists (CAP) submitted comments in response to a request for information on the Centers for Medicare & Medicaid...
The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.
CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:
- Genetic Testing for Heritable Thoracic Aortic Disease (L39933)
- Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935)
The LCDs will take effect Aug. 17 in 23 states.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025
TELCOR Acquires Sample Healthcare to Lead AI-Driven Transformation of Revenue Cycle Operations
Lincoln, NE — April 1, 2026 — TELCOR Inc, a leading provider of healthcare technology solutions for laboratories and healthcare facilities, today...
CMS Adopts Final Rule Phasing Out Fax and Mail for Health Care Claims Attachments
The Centers for Medicare & Medicaid Services (CMS) issued a final rule on national standards for electronic claims attachments and signatures,...